Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCX9930 monotherapy versus continued C5 inhibitor therapy in adults with paroxysmal nocturnal hemoglobinuria and inadequate response to C5 inhibition
2020-004438-39Phase 2Terminated
- Sponsor
- BioCryst Pharmaceuticals, Inc.
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of vimircopan in paroxysmal nocturnal hemoglobinuria (PNH) (2 arms), sponsored by BioCryst Pharmaceuticals, Inc. Primary endpoint: Change from baseline in hemoglobin. Started Jun 2021; status: terminated.
02
Drugs
vimircopan
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on 2020-004438-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004438-39.